In this episode of the Psychedelic Spotlight podcast, we feature Jemie Sae Koo, CEO and Founder of Psychable.
Similar Posts
Psychedelic Spotlight Interview with Rabbi Zac Kamenetz
In this episode of the Psychedelic Spotlight podcast, we speak…
Interview with Doug Drysdale, CEO, Cybin Inc
Doug talks about the company’s mission to revolutionize mental healthcare, how Cybin is delivering powerful and effective therapies, and why being the first psychedelic-based company to list on the New York Stock Exchange was a natural fit. Cybin can be found on the NYSE under the ticker symbol $CYBN.
Fixing Your Nervous System Dysregulation May Fix Your Anxiety and Depression with John Wood
In this episode, Sacha Hebbert and John Wood dive into a cautionary tale about the darker side of the psychedelic industry, where cults, and snake oil svengalis pray on open seekers all the time.
Interview With Ronan Levy
In this episode of the Psychedelic Spotlight podcast, we catch up with Ronan Levy, Co-Founder and Executive Chairman of Field Trip Health, and discuss the significance behind the company’s recent opening of its psilocybin research and cultivation facility in Jamaica along with the company’s recent listing on the OTCQX.
Interview with Sam Chapman, Executive Director of the Healing Advocacy Fund
This week on the Psychedelic Spotlight podcast, we talk with Sam Chapman. Sam is a resident of Portland, Oregon, he was the Campaign Manager for Oregon Measure 109, and is now the Executive Director of the Healing Advocacy Fund, a nonprofit organization dedicated to supporting the nation’s first regulated psilocybin therapy program.
BIG UPDATE On The LARGEST Psychedelic Therapy Clinical Trial: CMPS’ Psilocybin-Depression Study
HUGE UPDATE: Compass Pathways, (NASDAQ: CMPS), completes the LARGEST Phase 2b psilocybin clinical study to treat treatment resistant depression (TRD).
This is the most important psychedelic therapy study that we know of because it is both the largest clinical trial testing psilocybin to date and it is also the most advanced in the clinical trial process.
In this episode we will discuss:
– The details of this trial and why it is so important;
– The big update that we have for you;
– When we can expect results;
– Where the field goes from here in the near future.
Timestamps:
0:00 – Intro
1:31 – What is Compass Pathways’ Phase2b trial and why is it important?
6:57 – The major Update on CMPS’ Clinical Trial
8:07 – Anticipated results date & what these results will mean for the psychedelic industry
Enjoy the episode!
Follow us on social media! 🙌
Instagram: @thepsychedelicinvestor
Facebook: @thepsychedelicinvestor
Want to collaborate? Send us an email at:
thepsychedelicinvestor@gmail.com
Music from:
www.bensound.com
Video editing: @themyaholy
Check out our Benziga discounts
https://benzinga.grsm.io/jameshallifax1834
https://benzinga.grsm.io/thepsychedelicinvestor
DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.
All of the information in this video is public information that James (The Psychedelic Investor) believes to be reliable but it is not guaranteed to be 100% accurate and as such should not be used as advice. Any opinions or thoughts from James (The Psychedelic Investor) are subject to change.
#CompassPathways #CMPS #PsychedelicTherapy